For PD-1/PD-L1 mAbs alone, FDA-approved settings now include melanoma, NSCLC, head and neck squamous cell carcinoma, urothelial carcinoma, clear cell renal cell carcinoma, hepatocellular carcinoma, Merkel Cell Carcinoma, mismatch repair (MMR)-deficient cancer of any origin and Hodgkin Lymphoma (www.fda.gov). This evidence concerns the gene PDCD1 and melanoma.